Paper
The therapeutic view separates large named disease portfolios from the diffuse OTHER bucket and shows where very old silence persists.
Which condition families still hold the largest stock of CT.gov studies unresolved at least ten overdue years beyond the two-year reporting mark? We analysed 249,507 eligible older closed interventional studies from the March 29, 2026 full-registry snapshot using one condition-family label per study. We defined ancient backlog as older studies with no posted results and at least ten overdue years beyond the two-year mark, then ranked large condition families. Oncology led the named-family table at 11,369 studies, while the broad OTHER bucket held 10,899 and cardiovascular followed at 6,545. Metabolic remained high on stock at 4,693, while healthy volunteers reached the highest large-family ancient-backlog rate at 31.5 percent. Ancient backlog separates diffuse registry stock from large disease portfolios and shows that very old silence remains prominent in major therapeutic areas. Condition families are keyword-derived registry groupings, so they approximate therapeutic portfolios rather than fixed clinical ontologies or mutually exclusive diagnoses within the registry as presented here.